HRP20221252T1 - Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom - Google Patents
Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom Download PDFInfo
- Publication number
- HRP20221252T1 HRP20221252T1 HRP20221252TT HRP20221252T HRP20221252T1 HR P20221252 T1 HRP20221252 T1 HR P20221252T1 HR P20221252T T HRP20221252T T HR P20221252TT HR P20221252 T HRP20221252 T HR P20221252T HR P20221252 T1 HRP20221252 T1 HR P20221252T1
- Authority
- HR
- Croatia
- Prior art keywords
- day
- gemcitabine
- patient
- use according
- bladder
- Prior art date
Links
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title claims 16
- 229960005277 gemcitabine Drugs 0.000 title claims 15
- 238000012377 drug delivery Methods 0.000 title claims 5
- 206010005003 Bladder cancer Diseases 0.000 title claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 title claims 2
- 238000000034 method Methods 0.000 title 1
- 210000003932 urinary bladder Anatomy 0.000 claims 14
- 229940126601 medicinal product Drugs 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 210000002700 urine Anatomy 0.000 claims 3
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 2
- 239000002357 osmotic agent Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949215P | 2014-03-06 | 2014-03-06 | |
| EP15711373.9A EP3113782B1 (en) | 2014-03-06 | 2015-03-06 | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
| PCT/US2015/019262 WO2015134911A1 (en) | 2014-03-06 | 2015-03-06 | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221252T1 true HRP20221252T1 (hr) | 2022-12-09 |
Family
ID=52697553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221252TT HRP20221252T1 (hr) | 2014-03-06 | 2015-03-06 | Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom |
| HRP20251264TT HRP20251264T1 (hr) | 2014-03-06 | 2015-03-06 | Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20251264TT HRP20251264T1 (hr) | 2014-03-06 | 2015-03-06 | Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom |
Country Status (24)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678308C2 (ru) | 2012-08-31 | 2019-01-25 | ТАРИС Биомедикал ЛЛК | Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина |
| HUE051336T2 (hu) | 2013-08-19 | 2021-03-01 | Taris Biomedical Llc | Többadagos gyógyszeradagoló eszköz |
| PL3113782T3 (pl) * | 2014-03-06 | 2023-01-23 | Taris Biomedical Llc | Układy podawania leku i sposoby leczenia raka pęcherza moczowego gemcytabiną |
| IL295592A (en) | 2016-05-06 | 2022-10-01 | Taris Biomedical Llc | A method for treating urothelial cancer in the lower system |
| SG11201913251VA (en) | 2017-07-25 | 2020-01-30 | Taris Biomedical Llc | Methods of treating tumor metastasis |
| EA202091143A1 (ru) * | 2017-11-08 | 2020-07-30 | ТЭРИС БАЙОМЕДИКАЛ ЭлЭлСи | Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина |
| AU2019315957A1 (en) | 2018-08-01 | 2021-02-18 | Taris Biomedical Llc | Methods of treating overactive bladder using trospium |
| WO2021066175A1 (ja) * | 2019-10-03 | 2021-04-08 | 生化学工業株式会社 | 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム |
| RU2713443C2 (ru) * | 2019-11-01 | 2020-02-05 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0 |
| EP4096686A4 (en) * | 2020-01-27 | 2024-01-10 | Isola Therapeutics, Inc. | TISSUE DOSAGE FOR LOCAL INTRALUMINAL DRUG ADMINISTRATION |
| CN112169066B (zh) * | 2020-10-29 | 2023-05-12 | 安徽省立医院(中国科学技术大学附属第一医院) | 具有控制器的连续缓释给药留置管 |
| CN113616666A (zh) * | 2021-08-24 | 2021-11-09 | 傅广波 | 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
| AU2003278881A1 (en) * | 2002-09-23 | 2004-04-08 | Microchips, Inc. | Micro-reservoir osmotic release systems and microtube array device |
| CN100548411C (zh) * | 2003-03-31 | 2009-10-14 | 精达制药公司 | 设置有内部压力释放部件的渗透泵 |
| US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| DK1933810T3 (da) | 2005-08-11 | 2013-01-28 | Childrens Medical Center | Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde |
| WO2008013589A2 (en) * | 2006-04-24 | 2008-01-31 | Gloucester Pharmaceuticals | Treatment of ras-expressing tumors |
| NZ585449A (en) | 2007-12-11 | 2012-07-27 | Massachusetts Inst Technology | Implantable drug delivery device and methods for treatment of the bladder and other body vestcles or lumens |
| WO2010019507A2 (en) | 2008-08-09 | 2010-02-18 | Massachusetts Institute Of Technology | Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues |
| BRPI1014771B1 (pt) | 2009-06-26 | 2020-04-14 | Liris Biomedical Inc | dispositivo de dispensação de droga |
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| US9017312B2 (en) * | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| PT3884988T (pt) * | 2009-12-17 | 2025-09-01 | Taris Biomedical Llc | Dispositivo implantável com tolerabilidade intravesical |
| WO2011089604A2 (en) * | 2010-01-20 | 2011-07-28 | Theracoat Ltd | Material and method for treating internal cavities |
| US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
| WO2012048104A1 (en) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Implantable drug delivery device with bladden retention feature |
| EP2624875A1 (en) | 2010-10-06 | 2013-08-14 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
| CN103379902B (zh) * | 2011-02-04 | 2015-11-25 | 塔里斯生物医药公司 | 用于低溶解度药物的控制释放的可植入装置 |
| RU2678308C2 (ru) * | 2012-08-31 | 2019-01-25 | ТАРИС Биомедикал ЛЛК | Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина |
| SG11201507294WA (en) | 2013-03-15 | 2015-10-29 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
| WO2014144066A1 (en) | 2013-03-15 | 2014-09-18 | Taris Biomedical, Inc | Drug delivery devices and methods for drug delivery |
| HUE051336T2 (hu) | 2013-08-19 | 2021-03-01 | Taris Biomedical Llc | Többadagos gyógyszeradagoló eszköz |
| CA2929554A1 (en) * | 2013-11-05 | 2015-05-14 | Taris Biomedical Llc | Osmotic drug delivery devices, kits, and methods |
| PL3113782T3 (pl) | 2014-03-06 | 2023-01-23 | Taris Biomedical Llc | Układy podawania leku i sposoby leczenia raka pęcherza moczowego gemcytabiną |
-
2015
- 2015-03-06 PL PL15711373.9T patent/PL3113782T3/pl unknown
- 2015-03-06 EP EP22196596.5A patent/EP4124339B1/en active Active
- 2015-03-06 SG SG11201607342QA patent/SG11201607342QA/en unknown
- 2015-03-06 SM SM20250385T patent/SMT202500385T1/it unknown
- 2015-03-06 PT PT157113739T patent/PT3113782T/pt unknown
- 2015-03-06 DK DK15711373.9T patent/DK3113782T3/da active
- 2015-03-06 CA CA2939979A patent/CA2939979C/en active Active
- 2015-03-06 RU RU2016136103A patent/RU2694902C1/ru active
- 2015-03-06 SM SM20220449T patent/SMT202200449T1/it unknown
- 2015-03-06 US US14/641,009 patent/US20150250717A1/en not_active Abandoned
- 2015-03-06 PL PL22196596.5T patent/PL4124339T3/pl unknown
- 2015-03-06 HR HRP20221252TT patent/HRP20221252T1/hr unknown
- 2015-03-06 RS RS20220937A patent/RS63675B1/sr unknown
- 2015-03-06 DK DK22196596.5T patent/DK4124339T3/da active
- 2015-03-06 IL IL247347A patent/IL247347B2/en unknown
- 2015-03-06 PT PT221965965T patent/PT4124339T/pt unknown
- 2015-03-06 RS RS20251017A patent/RS67337B1/sr unknown
- 2015-03-06 AU AU2015226901A patent/AU2015226901B2/en active Active
- 2015-03-06 LT LTEP22196596.5T patent/LT4124339T/lt unknown
- 2015-03-06 EP EP15711373.9A patent/EP3113782B1/en active Active
- 2015-03-06 HR HRP20251264TT patent/HRP20251264T1/hr unknown
- 2015-03-06 CN CN201580011259.9A patent/CN106102751A/zh active Pending
- 2015-03-06 ES ES15711373T patent/ES2930435T3/es active Active
- 2015-03-06 MX MX2016011333A patent/MX2016011333A/es unknown
- 2015-03-06 CN CN202510128139.2A patent/CN119950539A/zh active Pending
- 2015-03-06 KR KR1020167027303A patent/KR102338079B1/ko active Active
- 2015-03-06 FI FIEP22196596.5T patent/FI4124339T3/fi active
- 2015-03-06 BR BR112016020381A patent/BR112016020381A8/pt not_active Application Discontinuation
- 2015-03-06 LT LTEPPCT/US2015/019262T patent/LT3113782T/lt unknown
- 2015-03-06 WO PCT/US2015/019262 patent/WO2015134911A1/en not_active Ceased
- 2015-03-06 HU HUE15711373A patent/HUE060704T2/hu unknown
- 2015-03-06 SI SI201532080T patent/SI4124339T1/sl unknown
- 2015-03-06 SG SG10202101978SA patent/SG10202101978SA/en unknown
- 2015-03-06 JP JP2016555554A patent/JP6901858B2/ja active Active
-
2019
- 2019-10-04 JP JP2019184023A patent/JP7061595B2/ja active Active
-
2020
- 2020-08-12 AU AU2020217383A patent/AU2020217383B2/en active Active
-
2021
- 2021-11-11 JP JP2021183995A patent/JP7383681B2/ja active Active
- 2021-12-23 US US17/561,540 patent/US20220117886A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/811,296 patent/US20220347091A1/en active Pending
- 2022-08-08 AU AU2022215156A patent/AU2022215156B2/en active Active
-
2023
- 2023-11-08 JP JP2023190543A patent/JP2024009034A/ja active Pending
-
2024
- 2024-03-11 IL IL311410A patent/IL311410B2/en unknown
- 2024-11-08 AU AU2024259822A patent/AU2024259822A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221252T1 (hr) | Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom | |
| HRP20211921T1 (hr) | Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s oksaliplatinom | |
| JP2017508749A5 (cg-RX-API-DMAC7.html) | ||
| BR112015005351A2 (pt) | sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior | |
| MX2024000737A (es) | Sistema de administracion, dispositivo de suministro, y dispositivo de notificacion para comunicar el estado de un dispositivo medico. | |
| FI3922279T3 (fi) | Lääkkeenantokoostumuksia ja niiden käyttötapoja | |
| Dhowan et al. | Simple minimally-invasive automatic antidote delivery device (A2D2) towards closed-loop reversal of opioid overdose | |
| RU2015109298A (ru) | Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина | |
| BR112017012706A2 (pt) | formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2021004546A (es) | Composiciones de suministro de farmaco implantables y metodos de uso de las mismas. | |
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| MX2019014942A (es) | Dispositivos de administracion de farmacos bioerosionables. | |
| MX2018004695A (es) | Composiciones de proteinas estables. | |
| NZ769954A (en) | Syringe devices for use in an emergency | |
| BR112018000039A2 (pt) | dispositivo de liberação de uso único | |
| MX2019015927A (es) | Composiciones para administración de fármacos y métodos de uso de las mismas. | |
| BR112015011294A2 (pt) | nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco de uso humano pentoxifilina | |
| BR112018000018A2 (pt) | dispositivo e sistema de liberação de uso único com aspectos de segurança | |
| AR096223A1 (es) | Pastilla de nicotina para administración oral | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| ES2572180T3 (es) | Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada | |
| MX387263B (es) | Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma. | |
| AR088369A1 (es) | Sistema de administracion de farmaco de dos fases |